Networking reception at BIO Europe
4 November 2024
Join us for an exciting evening at The Royal Norwegian Embassy in Stockholm, in conjunction with the anniversary BIO-Europe conference, with a focus on knowledge sharing and networking in an unique setting with other key stakeholders from the international life science industry.
The reception will feature a concise programme showcasing distinguished speakers who will provide valuable insights and advice pertinent to the Norwegian life sciences ecosystem. Their presentations aim to inspire attendees and contribute to discussions focused on future growth ambitions.
Keynote Speakers:
- Prof. Carl Borrebaeck: A renowned professor and serial entrepreneur known for his extensive contributions to the field.
- Dr. Katharina Kreymborg: Senior Vice President and Chief Scientific Officer at Curie.bio, bringing a wealth of knowledge and experience to the conversation.
- Dr. Magnus R. Björsne: MBA, Assoc. Prof. , Head of BioVenture Innovation Unit, CEO AstraZeneca BioVentureHub (TBC).
Following the programme, enjoy a networking dinner that offers the opportunity to build meaningful connections with leaders and innovators in the field. This event is a valuable opportunity to engage with relevant international stakeholders and strengthen the Norwegian presence within the global life sciences landscape.
Practical information
Due to limited capacity, please note that only a portion of those registering will receive an official invitation if the maximum number of attendees is exceeded. Thank you for your understanding.
Important conditions
Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.
Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.
Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.